[go: up one dir, main page]

GB202318820D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB202318820D0
GB202318820D0 GBGB2318820.4A GB202318820A GB202318820D0 GB 202318820 D0 GB202318820 D0 GB 202318820D0 GB 202318820 A GB202318820 A GB 202318820A GB 202318820 D0 GB202318820 D0 GB 202318820D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2318820.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB2318820.4A priority Critical patent/GB202318820D0/en
Publication of GB202318820D0 publication Critical patent/GB202318820D0/en
Priority to ARP240103355A priority patent/AR134568A1/en
Priority to TW113147576A priority patent/TW202542186A/en
Priority to PCT/EP2024/085100 priority patent/WO2025120171A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2318820.4A 2023-12-08 2023-12-08 Antibodies Ceased GB202318820D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2318820.4A GB202318820D0 (en) 2023-12-08 2023-12-08 Antibodies
ARP240103355A AR134568A1 (en) 2023-12-08 2024-12-06 ANTIBODIES
TW113147576A TW202542186A (en) 2023-12-08 2024-12-06 Antibodies
PCT/EP2024/085100 WO2025120171A1 (en) 2023-12-08 2024-12-06 Antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2318820.4A GB202318820D0 (en) 2023-12-08 2023-12-08 Antibodies

Publications (1)

Publication Number Publication Date
GB202318820D0 true GB202318820D0 (en) 2024-01-24

Family

ID=89575936

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2318820.4A Ceased GB202318820D0 (en) 2023-12-08 2023-12-08 Antibodies

Country Status (4)

Country Link
AR (1) AR134568A1 (en)
GB (1) GB202318820D0 (en)
TW (1) TW202542186A (en)
WO (1) WO2025120171A1 (en)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (en) 1987-07-01 1987-07-01 Novo Industri As immobilization
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP2007536898A (en) 2003-07-01 2007-12-20 セルテック アール アンド ディ リミテッド Modified antibody Fab fragment
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EP2164873B2 (en) 2007-05-31 2018-09-12 Genmab A/S Stable igg4 antibodies
ES2667729T3 (en) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusions of antibodies with double specificity
HUE033438T2 (en) 2008-09-26 2017-11-28 Ucb Biopharma Sprl Biological products
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
CN103946237B (en) 2011-11-11 2017-04-12 Ucb医药有限公司 albumin binding antibodies and binding fragments thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
BR112018071288A2 (en) 2016-05-01 2019-02-26 Ucb Biopharma Sprl modified affinity serum protein carrier binding domain
TWI782930B (en) * 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
GB202015235D0 (en) 2020-09-25 2020-11-11 Ucl Business Plc Anti-CD45 antibodies and related therapeutics
AU2021359092A1 (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules that multimerise cd45

Also Published As

Publication number Publication date
AR134568A1 (en) 2026-01-28
WO2025120171A1 (en) 2025-06-12
TW202542186A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
HUE069018T2 (en) Anti-ccr8 antibodies
GB2614651B (en) Antibodies
IL324435A (en) Anti-il1rap antibodies
GB2627309B (en) Antibodies
IL317231A (en) Anti-bcma antibodies
GB202304512D0 (en) Antibodies
GB202217924D0 (en) Antibodies
GB202309981D0 (en) Antibody
GB202204159D0 (en) Antibodies
IL325202A (en) Anti-fibril antibodies
IL320725A (en) Anti-beta-catenin antibodies
GB202400120D0 (en) Anti-pgdh antibodies
GB202319255D0 (en) Anti-UNC5C antibodies
GB202318820D0 (en) Antibodies
GB202317371D0 (en) Anti-unc5c antibodies
GB202317192D0 (en) Anti-agr2 antibodies
GB202317189D0 (en) Anti-AGR2 antibodies
GB202317188D0 (en) Anti-AGR2 antibodies
GB202317187D0 (en) Anti-AGR2 antibodies
GB202316016D0 (en) Antibodies
GB202311470D0 (en) Anti-BST2 antibodies
GB202311473D0 (en) Anti-ifnl1/reg3a antibodies
GB202309920D0 (en) Antibodies
GB202308898D0 (en) Anti-fibril antibodies
GB202308884D0 (en) Anti-fibril antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)